Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions.

Peng S, Qin M, Song G, Mao Q, Liu Z, Nie W

Open source

DOI
10.3389/fimmu.2026.1859601
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1859601,
  title = {Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions.},
  author = {Peng S and Qin M and Song G and Mao Q and Liu Z and Nie W},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1859601},
  url = {https://doi.org/10.3389/fimmu.2026.1859601}
}

RIS

TY  - JOUR
TI  - Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions.
AU  - Peng S
AU  - Qin M
AU  - Song G
AU  - Mao Q
AU  - Liu Z
AU  - Nie W
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1859601
UR  - https://doi.org/10.3389/fimmu.2026.1859601
ER  - 

APA

S, P., M, Q., G, S., Q, M., Z, L., & W, N. (2026). Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1859601

Source records